For media enquiries please contact Communications and Media Relations Manager, Ed Sexton. If you have an out of hours media enquiry please call 07825 942 934 or email email@example.com
BIA welcomes Budget announcements to improve access to scale-up capital in response to Patient Capital Review
The Chancellor has today announced the outcome of the Patient Capital Review, which will deliver a £20bn package to support investment in innovative companies over the next 10 years. The Review was launched by chancellor Phillip Hammond a year ago and has been looking at how to increase access to finance, and especially long-term investment, for innovative growing companies. The outcome of the review has been hotly anticipated by the bioscience sector and key policies announced today were called for in the recent BIA response to the Patient Capital Review.
BIA CEO Steve Bates responds on European Medicines Agency move from London to Amsterdam
"Today’s government response to the Accelerated Access Review is a key piece in the jigsaw of UK government life science policy that will set the environment for our sector in the lead up to Brexit and beyond."
Following the BIA AGM last week, the Association has announced the new members who have been elected to its Board.
The Biotech Financing Update, January-June 2017, offers an update on the figures from the annual finance report – ‘Building something great: UK’s Global bioscience cluster’ - that the BIA produced in conjunction with their data partner Informa Pharma Intelligence. This snapshot takes a look at the headline data for the first half of 2017 and will be updated in January 2018 when the full year data will be released.
BIA CEO, Steve Bates,responds to Prime Minister Theresa May’s Florence speech.
The BIA has today (Friday 22 September) welcomed the government’s proposal to establish a new National Investment Fund to support the growth of innovative UK bioscience companies.
BIA and MHRA publish report following joint conference ‘Innovation in life sciences in a changing and dynamic environment’
The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the sector to discuss some hot topics and important developments that are having an impact on the changing and dynamic UK life sciences ecosystem.
BIA polling signals that leadership, alignment and buy-in key to deliver accelerated access in the UK
Responding to a House of Lords inquiry on life sciences and the industrial strategy, the BioIndustry Association has published new data which reveals that the majority of health care professionals are not aware of the Accelerated Access Review or previous government-led initiatives aimed at improving the adoption of innovation across the NHS.
The BIA and ABPI have welcomed the UK Government’s latest Brexit position paper on ‘Collaboration on science and innovation’. The UK Government’s position follows a prolonged effort from the life sciences industry to establish Government consensus on key Brexit issues.